Yujie Cui

Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer

Yate-Ching Yuan, L. Bosserman, J. S. Lee, 2022, Cancers.

Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer

J. Waisman, J. S. Lee, P. Frankel, 2022, Cancers.

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Jeff Trent, T. Dorff, S. Highlander, 2022, Nature Medicine.

Growth of the Social #RadOnc Network on Twitter.

A. Amini, B. Kavanagh, P. Frankel, 2020, Practical radiation oncology.

Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial

A. Sette, P. Frankel, J. Zaia, 2022, The Lancet Microbe.

Phase 2 prospective open label study of neoadjuvant nab‐paclitaxel, trastuzumab, and pertuzumab in patients with HER2‐positive primary breast cancer

J. Waisman, P. Frankel, G. Somlo, 2022, Cancer.

Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer

J. Waisman, J. S. Lee, P. Frankel, 2023, Cancer Immunology, Immunotherapy.